S. Huang - US FDA, Silver Spring, MD USA

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 22 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Grapefruit Juice (Gfj)-Drug Interactions: Where Are We

Z. Zhou,X. Yang, Y. Li, N. Zhou, L. Zhang,S. Huang, R. Madabushi,A. Ramamoorthy

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021): S22-S22

引用0浏览0引用

QUANTIFICATION OF CRITICAL MECHANISMS FOR STATIN DRUG INTERACTIONS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING

K. Alam,S. Chung,N. Isoherranen,S. Huang

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2020): S46-S46

引用0浏览0引用

MAJOR DIFFERENCES IN ADVERSE EVENTS WITH ANTIPSYCHOTIC DRUGS BETWEEN PEDIATRIC AND ADULT PATIENTS

X. Liu, P. Schuette,D. Green, J. La,J. Burnham,J. van den Anker,S. Huang,G. J. Burckart

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2018): S42-S43

引用0浏览0引用

INTACT NEPHRON THEORY MAY NOT FULLY EXPLAIN THE EFFECT OF SEVERE RENAL IMPAIRMENT FOR DRUGS ACTIVELY SECRETED VIA RENAL ORGANIC ANION TRANSPORTERS

C. -H. Hsueh,P. Zhao, W. Hsu,L. Zhang,K. Giacomini,S. Huang

CLINICAL PHARMACOLOGY & THERAPEUTICSno. S1 (2017): S18-S19

引用0浏览0引用

COMPARISON OF THE EFFECT OF CHRONIC KIDNEY DISEASE (CKD) ON PHARMACOKINETICS OF OATP, CYP2D6, AND CYP3A SUBSTRATES

K. Yoshida,B. Sun,P. Zhao, L. Zhang,S. Huang

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2016): S76-S76

引用0浏览0引用

THE ACTIVITIES OF ORGANIC ANION TRANSPORTERS, OATP1B1/1B3 AND OAT1/3 AREMODULATED BY UREMIC TOXINS. C

C. Hsueh,K. Yoshida, T. Meyer,L. Zhang,S. Huang,K. Giacomini

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2016): S15-S15

引用0浏览0引用

ANALYSIS OF THE EFFECT OF VARIOUS DEGREES OF RENAL IMPAIRMENT ON THE PHARMACOKINETICS OF NONRENALLY ELIMINATED DRUGS

K. Yoshida, C. K. Yeung, M. Kusama,H. Zhang, I. Ragueneau-Majlessi, S. Argon,P. Zhao, L. Zhang, I. Zineh, Y. Sugiyama,S. Huang

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2015): S92-S92

引用0浏览0引用

PREDICTING CYP3A4 INHIBITION IN CYP2D6 POOR METABOLIZERS USING PBPK MODELING AND SIMULATION: FESOTERODINE AS AN EXAMPLE

M. L. Vieira,P. Zhao,M. Kim, S. Apparaju,S. Huang

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2012): S53-S53

引用0浏览0引用

COMPARISON OF INCLUSION OF WOMEN IN EARLY VERSUS LATE PHASE CLINICAL TRIALS IN NEW DRUG AND BIOLOGICS APPLICATIONS RECENTLY APPROVED BY THE US FDA

L. W. Chinn, R. Poon, E. O. Fadiran,A. Parekh,S. Huang, L. Zhang

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2012): S97-S97

引用0浏览0引用

WHAT CRITERIA MAY BE APPROPRIATE IN DETERMINING THE NEED FOR IN VIVO EVALUATION OF A NEW MOLECULAR ENTITY'S (NME'S) POTENTIAL TO INHIBIT OATP1B1 (ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1)

J. Vaidyanathan,V. Arya,S. Agarwal,M. de L. T. Vieira,P. Zhao,S. Huang, L. Zhang

CLINICAL PHARMACOLOGY & THERAPEUTICSno. SUPnan (2012): S53-S53

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn